Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study

PURPOSE: Concomitant treatment with radium-223 and paclitaxel is a potential option for cancer patients with bone metastases; however, myelosuppression risk during coadministration is unknown. This phase Ib study in cancer patients with bone metastases evaluated the safety of radium-223 and paclitax...

Descripción completa

Detalles Bibliográficos
Autores principales: Geva, Ravit, Lopez, Juanita, Danson, Sarah, Joensuu, Heikki, Peer, Avivit, Harris, Samuel J., Souza, Fabricio, Pereira, Kaline M. C., Perets, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451720/
https://www.ncbi.nlm.nih.gov/pubmed/30547207
http://dx.doi.org/10.1007/s00259-018-4234-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451720/
https://www.ncbi.nlm.nih.gov/pubmed/30547207
http://dx.doi.org/10.1007/s00259-018-4234-6

Ejemplares similares